Sudarshan Padmanabhan

Yes. Sir, my question is, if I look at the U.S. business, I mean, we have a fair basket of ophthalmic products. I mean, if you look brinzolamide being one and certain other products like [inaudible 0 17:46], etcetera. So if you can give some color with respect to how do we see launches in the U.S. and probably traction in the existing products?

Do we have any aspiration for, say, FY27, FY28 for European and U.S. business? And specifically with respect to Vigamox, how do we see this product gathering momentum and how big would this product end up being?

And with respect to the cash that is coming in primarily post the transaction, one, I mean, what should be the use of it? Because if I look at the domestic business, I mean, as you mentioned, I think the anti-infectives has been a little bit of a joker in the pack, a little bit more volatile than what was expected. So, I mean, would you be primarily looking to repay debt?